Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Aaron Gerds, a hematologist from the Cleveland Clinic, to discuss the current treatment algorithms for myeloproliferative neoplasms (MPNs), specifically focusing on polycythemia vera (PV) and essential thrombocythemia (ET).

Join us as we delved into:

The diagnostic criteria for PV and ET, including the significance of JAK2 mutations and erythropoietin (EPO) levels
The role of bone marrow biopsies in diagnosing and managing these conditions
Treatment options for PV, including hydroxyurea, ropeginterferon alfa-2b, and ruxolitinib, as well as the approval of rusfertide
The importance of risk stratification based on patient age and history of thrombosis
The management of side effects associated with various treatment options
The clinical utility of monitoring JAK2 allele burden and its implications for patient management
Insights into the treatment landscape for ET, including the use of antiplatelet therapy and the role of acquired Von Willebrand disease

Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of managing PV and ET.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

⁠X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in hematological and oncological care!

#PolycythemiaVera, #EssentialThrombocythemia, #MPN, #JAK2, #OncologyBrothers

Polycythemia vera (PV) and Essential thrombocythemia (ET) Treatment Algorithm: Dr. Aaron Gerds

Oncology Brothers: Practice-Changing Cancer Discussions

Polycythemia vera (PV) and Essential thrombocythemia (ET) Treatment Algorithm: Dr. Aaron Gerds